A new, highly mutated COVID-19 variant nicknamed “Cicada” is once again putting the spotlight on public health officials in the United States. Officially designated BA.3.2 and part of the Omicron lineage, the strain has been detected in at least 25 states. Yet it still makes up a tiny sliver of overall cases, with national COVID numbers continuing to trend downward.
The nickname comes from evolutionary biologist Dr. T. Ryan Gregory, who noted the variant’s cicada-like behavior: it surfaced in South Africa in late 2024, seemed to vanish, and has now re-emerged in the U.S. via travelers and clinical samples starting in early 2026. What truly stands out is its staggering number of mutations—roughly 70 to 75 changes in the spike protein alone when compared with the JN.1 and LP.8.1 strains that the current 2025–2026 COVID vaccines were built around.
That level of genetic drift has vaccine skeptics asking the obvious question: if the shots were designed for strains that no longer dominate, how much protection can they really offer against infection or transmission from Cicada? Lab data already hints at meaningful immune evasion, and many observers point out that this pattern has repeated with every major Omicron offshoot. Despite official assurances that vaccines still guard against severe outcomes, the rapid evolution of the virus continues to expose the limitations of a strategy built on chasing an ever-changing target with updated boosters.
As of mid-February 2026, the CDC has found BA.3.2 traces in wastewater from 25 states, a few traveler samples, and scattered clinical cases. Nationally the variant accounts for less than 0.2 percent of sequenced samples—hardly a surge—but it has climbed higher in parts of Europe. Symptoms mirror other recent Omicron relatives: sore throat, runny nose, headache, fatigue, cough, and occasional loss of taste or smell. No evidence yet shows Cicada causes worse disease than its predecessors.
Critics of the current approach argue that endless booster campaigns may be hitting diminishing returns, especially when the virus mutates faster than vaccine updates can catch up. They point to the possibility of “immune imprinting,” where repeated shots trained on outdated strains could actually blunt the body’s broader response to new variants. Rather than pushing universal vaccination for a low-risk variant in a population with widespread prior exposure, many now call for greater emphasis on personal risk assessment, natural immunity from past infection, and basic measures like ventilation and early treatment.
Health officials continue genomic surveillance and have not labeled Cicada a “variant of high concern.” Still, the emergence of yet another immune-evading strain underscores a simple reality: the virus is evolving, and relying primarily on vaccines formulated for yesterday’s version may not be the long-term solution many hoped for. Individuals—especially the elderly or those with serious underlying conditions—should consult their own doctors, weigh the data, and decide what makes sense for their health rather than following one-size-fits-all guidance.
SOURCES:
New COVID Variant ‘Cicada’ Is Spreading in 25 States. These Are Its Symptoms
What we know about the new ‘cicada’ COVID-19 variant | PBS News
New ‘Cicada’ COVID variant is spreading in the U.S.—here’s what to know | Scientific American
See where COVID variant BA.3.2 has been detected in the US
New COVID-19 Cicada Variant: What to Know
